Glaucoma Trial, Recruiting NCT07462000 Sponsor: Military Institute od Medicine National Research Institute Condition: Glaucoma
Back to Glaucoma

Glaucoma Trial, Recruiting

NCT07462000
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • You must be 18 years of age or older.
  • You must be scheduled to have cataract surgery (a procedure to remove the cloudy lens in your eye and replace it with an artificial one).
  • You must be able to read and sign a consent form agreeing to take part.
  • If joining the glaucoma group: you must have been diagnosed with a specific type of glaucoma called primary open-angle glaucoma, also have a cataract, and be planned for a combined surgery that treats both conditions at once.
  • If joining the comparison group: you must have a cataract but no glaucoma and no other serious eye conditions.

Who may not be able to join:

  • You are under 18 years of age.
  • You are currently pregnant or breastfeeding.
  • Your vision in the eye being studied is severely reduced — worse than being able to count fingers held up in front of you.
  • You have a type of glaucoma other than primary open-angle glaucoma (for example, angle-closure, secondary, or neovascular glaucoma).
  • You have had a previous operation inside the eye being studied, including past glaucoma surgery, retinal surgery, corneal transplant, or laser vision correction surgery.
  • You have had or currently have a condition called uveitis (inflammation inside the eye).
  • You have another serious long-term eye disease in the eye being studied (beyond cataract, or glaucoma if you are in the glaucoma group).
  • You are unable to attend follow-up appointments or complete the steps required by the study.

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 8 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Marek Rękas, MD, PhD, Military Institute od Medicine National Research Institute

Phone: 0048665 707 626

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Military Institute od Medicine National Research Institute
Registry
ClinicalTrials.gov
Start date
21 January 2026
Est. completion
21 January 2027

Where this trial is recruiting

🇵🇱 Poland

Primary endpoints

IOP; Visual Field; BCVA; Protein expression; RNFL

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 8 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov